Danish Precocious Puberty Study - DAPP Study A National Cohort Study on Incidence and Etiologies for Precocious Puberty

Puberty, Precocious Clinical Trial

— DAPP  

Official title:

Danish Precocious Puberty Study (DAPP Study) A National Cohort Study on Incidence and Etiologies for Precocious Puberty

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05957991
• Other study ID #: DanishPrecociousPubertyStudy
• Status: Not yet recruiting
• Start date: September 1, 2023
• Est. completion date: September 2030

Study information

• Verified date: July 2023
• Source: Copenhagen University Hospital at Herlev
• Contact: Rikke B Jensen, MD PhD
• Phone: +4561332368
• Email: rikke.beck.jensen[@]regionh.dk
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

There is an urgent need to obtain more knowledge about the influence of weight and metabolism on the timing and progression of puberty. The age of pubertal onset has been constantly declining during the last decades and extremely early maturation may have yet unseen consequences for the psychosocial development of the child as well as detrimental long-term health consequences. Studies have shown that girls with early-onset puberty are more likely than their peers to enter sexual relationships at a younger age, to experience more psychological distress, and to engage in risk-taking behaviors. In addition, early maturation may have long-term health consequences since earlier menarche is associated with an increased risk of all-cause mortality and cardiovascular disease later in life in large epidemiological studies. The exact aetiology for the earlier onset of puberty in the general population remains to be elucidated, and the cause is probably to be found in a complex interplay between genetic, epigenetic, environmental and metabolic factors. However, world-wide there is a concerning increasing prevalence of overweight in childhood and early puberty is one of many consequences of this. Environmental factors such as endocrine disrupting chemicals have been suggested to play a role for both obesity and precocious puberty either directly or through epigenetic moderation. The current study of a Danish National cohort will explore the incidence and aetiology of precocious puberty for better treatment and prevention. Furthermore, a placebo-controlled randomized controlled trial may give a novel mechanistic insight of the interplay between insulin sensitivity and sex steroids. To our knowledge this study is the first of its kind and may lead to novel alternative treatment strategy for overweight girls with early puberty that may have beneficial effects on long-term morbidity and mortality.

Description:

Original title of the project: Danish Precocious Puberty Study (DAPP study)

Project leaders and trial site: Principal investigator: Rikke Beck Jensen, MD PhD DMSc, Department of Children and Adolescents - Herlev Hospital Borgmester Ib Juuls Vej 101, 2730 Herlev, Denmark

Trial Site: 17 pediatric departments in Denmark

Purpose of the study: The development of precocious puberty is a growing problem worldwide. Breast development is observed as early as preschool age, which can have serious consequences for girls' quality of life. Previous studies have also found a correlation between early puberty and increased risk of diseases later in life. Lifestyle factors causing obesity have been suggested as a cause for the declining age of pubertal onset. Endocrine disrupting chemicals in our environment likely play a role as well. The purpose of this study is to determine the incidence of children experiencing early puberty in Denmark and to investigate the factors influencing the timing of pubertal onset. Our hypothesis is that environmental factors such as lifestyle and exposure to endocrine disrupting chemicals may affect pubertal onset either directly or through epigenetic changes.

Method, design and research procedures: The project is a national cohort study that will take place at 17 pediatric departments in Denmark. We will include all children referred with precocious puberty to the country's pediatric departments over a period of 3 years (September 2023-May 2026). We will examine the number of children referred with precocious puberty and investigate their BMI, metabolic function, levels of endocrine disrupting chemicals, as well as the genetic and epigenetic patterns. All examinations will be conducted at the 17 pediatric departments by doctors or nurses experienced in working with children. The study includes a clinical examination with pubertal assessment. Additionally, the children's growth will be assessed by measuring height, weight, hip-waist ratio, and blood pressure.

The clinical examination is supplemented by urine collection (approximately 50 ml) and blood sampling (approximately 35 ml). In the blood sample analyses of hormones, growth factors, markers for glucose metabolism, and blood lipids will be performed. The content of various endocrine disrupting chemicals such as phthalates and pesticides is determined in the urine.

DNA is isolated from the blood for investigation of genetic polymorphisms (single nucleotide polymorphisms, SNPs). We will focus on genes and variants with known or theoretical effects on hormone production and insulin sensitivity. Specific "primers" will be used for known SNPs or SNP arrays containing common variants found in more than 1% of the population. Methylation of DNA, known as epigenetics, will also be investigated. We will not examine hereditary diseases, and since we only examine known variants, no secondary findings will occur.

A questionnaire survey will be conducted as part of the study to map the children's early growth patterns, health, physical activity, as well as the growth and pubertal development of their parents. In addition, there are questions for both parents and children to determine the children's quality of life. The questionnaires are filled out online in REDCap, a secure web application for building and managing databases and online surveys.

Study participants: Approximately 1500 children will be recruited from the 17 pediatric departments in Denmark. This corresponds to the number of children expected to be referred to pediatric departments each year in a three year period based on previous registry data with clinical signs of early puberty.

Inclusion criteria: All children referred for suspected precocious puberty with one of the following ICD10 codes will be included: DE301, DE228A, DE308A, DE270B, DE308, DE309, DZ003. Patients with cancer or chronic diseases (e.g., previous malignant disease, chemotherapy, radiation, or known genetic disease) will also be included, even though these conditions themselves can affect pubertal onset. These patients are included to estimate the number of children with precocious puberty per year in Denmark.

Exclusion criteria: If we observe unexpected psychological or physical reactions or if participants are deemed unsuitable or withdraw their participation, they can be excluded at any time.

Recruitment of participants: The children will be recruited from all 17 pediatric departments, where they are referred by their general practitioners or school health nurses with signs of precocious puberty. All patients meeting the criteria for inclusion in the study will be invited to participate throughout the three-year inclusion period. Parents of potential participants will receive information about the study in their digital mailbox before their visit to the pediatric department, so they can bring a support person

Side effects, risks, and disadvantages: This research project involves no known health risks, side effects, or other burdens for the participants. However, some children may find the blood sampling procedure slightly uncomfortable, and they are offered a numbing patch to anesthetize the skin where the blood sample is taken. Pubertal assessment may be perceived as intrusive for some children, so all children will be examined by clinical staff experienced in pubertal assessment in children. Body composition will be assessed using bioimpedance, which can measure fat percentage in some of the pediatric departments. Children will not be exposed to radiation or radioactivity.

Financial considerations: Data collection for the study will be covered by a research grant from the Novo Nordisk Foundation totaling 9.89 million DKK. Expenses for blood and urine sample analyses will be covered by funds from private foundations. The study is not supported by the pharmaceutical industry, and there are no commercial interests associated with the study. Information about the financial support will be provided in the participant information material. Compensation for participation is not offered. No members of the project group have a specific affiliation with the funding sources, and the execution of this research project is solely controlled by the project leader, who has no financial interest in the research project's results.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 1500
• Est. completion date: September 2030
• Est. primary completion date: August 30, 2026
• Gender: All
• Age group: 3 Years to 10 Years

Eligibility

Inclusion Criteria:

• All children (> 4 years of age) referred to one of the seventeen collaborating pediatric departments with one of the following diagnosis (ICD10)

• DE301

• DE228A

• DE308A

• DE270B

• DE308

• DE309

• DZ003

Exclusion Criteria:

• If the investigating doctor at the local hospital observes unexpected psychological/physical reactions, or a participant is found to be unsuitable (cf. inclusion criteria) or regrets agreeing to participate, this person can at any given time be excluded.

Related Conditions & MeSH terms

• Puberty, Precocious

Intervention

Drug:
• Metformin Hydrochloride tablet
Treatment with metformin
• Placebo
Treatment with placebo

Behavioral:
• Lifestyle intervention
Changing behaviour on diet and excersise
• No lifestyle intervention
No changes in behaviou on diet and excersise

Locations

Country	Name	City	State
Denmark	Univerity Hospital Aalborg	Aalborg
Denmark	University Hospital Aarhus	Aarhus
Denmark	Copenhagen University Hospital - Herlev	Herlev	Capital Region
Denmark	University Hospital Odense	Odense
Denmark	University Hospital Roskilde	Roskilde

Sponsors (1)

Lead Sponsor	Collaborator
Copenhagen University Hospital at Herlev

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of CPP among all children referred to 18 Danish pediatric departments during a 3-year period	Number of patients referred who have precocious puberty	3 years
Primary	BMI (SDS) at pubertal onset	Adiposity in children with precocious puberty	3 years
Primary	Genome-wide methylation patterns in peripheral blood associated with CPP and treatment	epigenetic alterations	3 years
Primary	Urinary EDC excretion profiles in CPP children compared to age-matched controls	endocrine disrupting chemicals associated to early puberty	3 years
Primary	Randomised placebo controlled trial	The effect of metformin and/or lifestyle intervention on pubertal development	3 years